Loading organizations...
§ Private Profile · Boston, MA, USA
biopharmaceutical company developing novel therapies for neurodegenerative diseases like Alzheimer's, ALS, and stroke.
Based in Boston, Massachusetts, AZTherapies is a private biopharmaceutical company developing treatments that target neuroinflammation to address neurodegenerative diseases such as Alzheimer's, ALS, and ischemic stroke cognitive impairment. The biotechnology firm operates with eleven to fifty employees and has secured over 109 million dollars in venture capital funding, including a 34 million dollar Series C round. Founded in 2011 by David Elmaleh, the organization advances multimodal candidates utilizing technology licensed from Harvard University and Massachusetts General Hospital. Following the clinical setback of its lead small molecule candidate in a 2021 Phase Three trial, the enterprise expanded its pipeline under Chief Executive Officer Marc de Garidel to include chimeric antigen receptor T regulatory cell therapies. Backed by investors like DRADS Capital and Spinnaker Capital, the business continues modifying disease progression for patients facing severe neurological conditions.
AZTherapies has raised $59.9M across 2 funding rounds.
AZTherapies has raised $59.9M in total across 2 funding rounds.
AZTherapies has raised $59.9M in total across 2 funding rounds.
AZTherapies's investors include Duopharma Biotech Berhad, Cosine, Tas Parafestas, Drads Capital, IBS Capital, Wexford Capital.
AZTherapies has raised $59.9M across 2 funding rounds. Most recently, it raised $33.6M Series C in October 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 2, 2020 | $33.6M Series C | Duopharma Biotech Berhad | — | Announced |
| Oct 17, 2019 | $26.3M Series C | Cosine, TAS Parafestas | Drads Capital, IBS Capital, Wexford Capital | Announced |